Update on regulation of GHRH and its actions on GH secretion in health and disease
Reviews in Endocrine and Metabolic Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 21, 2025
Language: Английский
The Potential Roles of 77C>T Variant and Growth Hormone-Releasing Hormone Elevation in Pituitary Adenoma Cases Associated with Acromegaly
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 27, 2025
Abstract
Background:
Acromegaly
(ACM)
is
an
endocrine
disorder
characterized
by
the
elevation
of
growth
hormone-releasing
hormone
(GHRH),
(GH),
and
insulin-like
factor-1
(IGF-1).
Objectives:
This
study
aims
to
elucidate
correlation
between
77C>T
(rs368475481)
variant
in
GHRH
gene
elevated
levels
patients
with
acromegaly.
Materials
Methods:
study,
conducted
from
January
August
2024,
analyzed
80
samples
Iraqi
acromegaly
collected
at
Diabetic
National
Center,
Al-Mustansiriyah
University,
alongside
healthy
individuals.
Growth
were
quantified
using
chemiluminescence
immunoassay,
while
measured
enzyme-linked
immunosorbent
assay
(ELISA).
The
SNP
was
detected
via
Sanger
sequencing
assess
genetic
variation
controls.
Results:
serum
GHRH,
GH,
IGF-1
compared
results
indicate
presence
rs368475481
amplified
fragment
(a
791
bp
amplicon
including
exons
2
3,
intron
2),
CC
homozygous
genotype
observed
(100%)
controls
40
(50%)
patients.
CT
heterozygous
present
Conclusion:
The
polymorphism
shown
be
associated
pituitary
adenomas,
which
cause
Language: Английский
Mention to Prof. Andrew V. Schally
Reviews in Endocrine and Metabolic Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Language: Английский
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(7), P. 3267 - 3267
Published: April 1, 2025
Growth
hormone-releasing
hormone
(GHRH)
antagonists
exert
antitumor
functions
in
different
experimental
cancers.
However,
their
role
combination
with
radiotherapy
non-small
cell
lung
cancer
(NSCLC)
remains
unknown.
Therefore,
we
investigated
the
radiosensitizing
effect
of
GHRH
NSCLC.
A549
and
H522
NSCLC
lines
were
exposed
to
ionizing
radiation
(IR)
MIA-602
MIA-690,
either
individually
or
combination.
Cell
viability
proliferation
evaluated
by
MTT,
BrdU,
flow
cytofluorimetry,
clonogenic
assays;
gene
protein
expression,
signaling
pathways,
apoptosis
analyzed
real-time
PCR,
Western
blot,
annexin
staining,
caspase-3
assay.
showed
effects
alone
potentiated
IR-induced
inhibition
proliferation.
The
MIA-690
IR
decreased
expression
receptor,
its
oncogenic
splice
variant
1,
IGF1
mRNA
levels.
Additionally,
cycle
inhibitors
proapoptotic
markers
upregulated,
whereas
cyclins,
MYC,
antiapoptotic
Bcl-2
downregulated.
Radioresistance
was
prevented
which
also
blunted
epithelial-mesenchymal
transition
enhancing
E-cadherin
reducing
mesenchymal,
oxidative,
proangiogenic
effectors.
Finally,
both
enhanced
radiosensitivity
primary
human
cells.
These
findings
highlight
potential
as
radiosensitizers
treatment.
Language: Английский
Ectopic GHRH production: revisiting a rare cause of acromegaly
Reviews in Endocrine and Metabolic Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 2, 2025
Language: Английский
Lanreotide protects against LPS-induced inflammation in endothelial cells and mouse lungs
Md Matiur Rahman Sarker,
No information about this author
Saikat Fakir,
No information about this author
Khadeja-Tul Kubra
No information about this author
et al.
Tissue Barriers,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 17, 2025
Somatostatin
is
expressed
in
various
tissues
-
including
the
hypothalamus
and
strongly
suppresses
Growth
Hormone
levels
to
maintain
homeostasis.
Synthetic
somatostatin
analogs
are
currently
used
clinics
treat
neuroendocrine
tumors
acromegaly.
An
emerging
body
of
evidence
suggests
that
those
synthetic
peptides
exert
anti-inflammatory
activities.
The
present
study
examines
effect
Lanreotide
(LAN)
on
Lipopolysaccharide
(LPS)-triggered
injury
endothelial
cells
mice.
Our
findings
indicate
LAN
effectively
mitigates
LPS-induced
hyperpermeability,
inflammation,
reactive
oxygen
species
(ROS)
generation
bovine
pulmonary
artery
(BPAEC)
human
lung
microvascular
(HULEC-5a).
A
murine
model
acute
was
also
utilized,
examine
effects
edema
inflammation.
observations
suggest
myosin
light
chain
2
(MLC2),
Cofilin,
extracellular
signal-regulated
kinase
1/2
(ERK1/2),
STAT1,
STAT3,
P38
activation;
edema.
In
conclusion,
based
aforementioned
observations,
it
suggested
counteracts
experimental
Language: Английский
Ceapin-A7 suppresses the protective effects of Octreotide in human and bovine lung endothelial cells
Saikat Fakir,
No information about this author
Madan Sigdel,
No information about this author
Md Matiur Rahman Sarker
No information about this author
et al.
Cell Stress and Chaperones,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 1, 2024
Endothelial
injury
can
be
the
cause
and
consequence
of
severe
inflammation
injury.
Synthetic
somatostatin
analogs
-
which
suppress
Growth
Hormone
are
FDA-approved
drugs
associated
with
anti-inflammatory
activities.
In
present
study
we
suggest
that
protective
activities
Octreotide
in
human
bovine
endothelial
cells
mitigated
by
Ceapin-A7,
is
an
activating
transcription
factor
6
suppressor.
To
function,
assessed
protein
expression
levels
key
cytoskeletal
proteins,
as
well
paracellular
permeability.
evaluate
inflammation,
measured
factors
promote
vascular
leak,
reactive
oxygen
species
generation.
Collectively,
our
supports
involvement
effects
barrier
function.
Language: Английский